Ultomiris®
What is Ultomiris®?
Ultomiris® (ravulizumab-cwvz) is a long-acting C5 complement inhibitor used to treat rare complement-mediated disorders such as paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).
It is a humanized monoclonal antibody — a type of laboratory-engineered antibody designed to reduce the likelihood of immune reactions when administered to humans.
How much does Ultomiris® cost?
Ultomiris® cost can vary depending on insurance provider and coverage. Our team at Rocky Mountain MS Clinic is committed to helping patients access affordable treatment and individualized financial support.
We work with nearly all major commercial insurers in the Rocky Mountain region, including Aetna, Anthem, Blue Cross Blue Shield, Cigna, Humana, PEHP, Select Health, Tricare, and others, as well as Medicaid and Medicare.
Our staff handles prior authorizations and benefits verification, and we assist patients in applying for copay and foundation programs to lower out-of-pocket costs.
Why Patients Choose Rocky Mountain Infusion Center to Receive Their Ultomiris® Infusion:
Clinical Excellence and Neurological Expertise
Our infusion center features a board-certified neurologist and a team of BSN-prepared Registered Nurses who specialize in infusion therapy for neurological and immune-mediated conditions.
Lower Costs and Financial Assistance
We manage all insurance coordination and guide patients through copay and financial assistance programs.
A recent Cigna report found that Patients treated at physician-owned infusion centers like Rocky Mountain MS Clinic’s often experience lower overall and out-of-pocket costs compared to hospital outpatient centers.
Established leader in MS & Neurological care
Over 35 years of serving patients across the Intermountain region with expert, compassionate neurological care.
How does Ultomiris® work?
Ultomiris® targets and blocks the C5 protein, a key component of the complement system — part of the body’s natural immune defense. In conditions like PNH and aHUS, the complement system becomes overactive, leading to red blood cell destruction (hemolysis) and damage to blood vessels.
By inhibiting the C5 protein, Ultomiris® helps control this excessive immune activity, protecting red blood cells and blood vessels while reducing symptoms and preventing disease-related complications.
The infusion clinic nurses are highly trained in Neurological conditions, personable, professional and careful. Having a doctor and team like this on your side of the fight against MS is invaluable.
They are constantly improving their in-house infusion center to ensure the comfort of their patients. The team there is professional and highly trained!
As someone who frequents their infusion center on a monthly basis, I can confidently say that it's top-notch. The staff at the infusion center are amazing, providing not only excellent medical care but also creating a comfortable and soothing environment for patients. Their dedication to patient comfort and well-being is evident in every aspect of the center.
Important Info
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Atypical Hemolytic Uremic Syndrome (AHUS)
Generalised Myasthenia Gravis
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Paroxysmal Nocturnal Hemoglobinuria (PNH): Approved on December 21, 2018
Atypical Hemolytic Uremic Syndrome (AHUS): Approved on October 18, 2019
Generalised Myasthenia Gravis: Approved on April 28, 2022
Neuromyelitis Optica Spectrum Disorder (NMOSD): Approved on March 25, 2024
Alexion Pharmaceuticals, Inc.